Differential microRNA expression in renal cell carcinoma

Oncology Letters

Volumn 6, Issue 3, 2013, Pages 769-776

  Cheng, Tingting ^a   Wang, Lina ^a   Li, Yuyao ^a   Huang, Chen ^b   Zeng, Lingxia ^b   Yang, Jin ^a  

^a First Affiliated Hospital   (China)

^b XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

microRNA; Radical nephrectomy; Renal cell carcinoma

Indexed keywords

MICRORNA; MICRORNA 141; MICRORNA 149; MICRORNA 21; MICRORNA 224; MICRORNA 34A; MICRORNA 429; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; DOWN REGULATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CAPSULE; KIDNEY CARCINOMA; MALE; TUMOR INVASION; TUMOR VOLUME; UPREGULATION;

EID: 84880424862     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1460     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2006. CA Cancer J Clin 56: 106-130, 2006.
2. Gottardo F, Liu CG, Ferracin M, et al: Micro-RNA profiling in kidney and bladder cancers. Urol Oncol 25: 387-392, 2007.
3. Escudier B: Advanced renal cell carcinoma: current and emerging management strategies. Drugs 67: 1257-1264, 2007.
4. Broghammer EL and Ratliff TL: Immunotherapy of urologic tumors: principles and progress. Urol Oncol 7: 45-56, 2002.
5. Mulders P, Figlin R, deKernion JB, et al: Renal cell carcinoma: recent progress and future directions. Cancer Res 57: 5189-5195, 1997.
6. Bukowski RM, Eisen T, Szczylik C, et al: Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: Survival and biomarker analysis. J Clin Oncol 25: 5023, 2007.
7. Motzer RJ, Hutson TE, Tomczak P, et al: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27: 3584-3590, 2009.
8. Hudes G, Carducci M, Tomczak P, et al: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271-2281, 2007.
9. Escudier B, Pluzanska A, Koralewski P, et al: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370: 2103-2111, 2007.
10. Jonasch E, Wood CG, Matin SF, et al: Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 27: 4076-4081, 2009.
11. Sternberg CN, Davis ID, Mardial J, et al: Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomised phase III trial. J Clin Oncol 28: 1061-1068, 2010.
12. Motzer RJ, Escudier B, Oudard S, et al: Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116: 4256-4265, 2010.
13. Walsh PC, Retik AB, Vaugh ED, et al (eds): Campbell's Urology. 8th edition. WB Saunders Company, Philadelphia, PA, pp2672-2719, 2002.
14. Chen X, Ba Y, Ma L, et al: Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other disease. Cell Res 18: 997-1006, 2008.
15. Chen ZY: The expression of circulated microRNA in ccRCC (unpublished PhD thesis). Zhongnan University, 2010.
16. Nakada C, Matsuura K, Tsukamoto Y, et al: Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c. J Pathol 216: 418-427, 2008.
17. Jung M, Mollenkopf HJ, Grimm C, et al: MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. J Cell Mol Med 13: 3918-3928, 2009.
18. Li M: MicroRNA expression profiling in renal cell carcinoma and its potential clinical significance (unpublished PhD thesis). Zhongshan University, 2009.
19. Huang Y, Dai Y, Yang J, et al: Microarray analysis of microRNA expression in renal clear cell carcinoma. Eur J Surg Oncol 35: 1119-1123, 2009.
20. Slaby O, Jancovicov J, Lakomy R, et al: Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy. J Exp Clin Cancer Res 29: 90, 2010.
21. Liu H, Brannon AR, Reddy AR, et al: Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma. BMC Syst Biol 4: 51, 2010.
22. Juan D, Alexe G, Antes T, et al: Identification of a microRNA panel for clear-cell kidney cancer. Urology 75: 835-841, 2010.
23. Chow TF, Youssef YM, Lianidou E, et al: Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis. Clin Biochem 43: 150-158, 2010.
24. Yi Z, Fu Y, Zhao S, Zhang X and Ma C: Differential expression of miRNA patterns in renal cell carcinoma and nontumorous tissues. J Cancer Res Clin Oncol 136: 855-862, 2010.
25. Mitchell PS, Parkin RK, Kroh EM, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105: 10513-10518, 2008.
26. Wei J, Gao W, Zhu CJ, et al: Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. Chin J Cancer 30: 407-414, 2011.
27. Tomimaru Y, Equchi H, Naqano H, et al: Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol 56: 167-175, 2012.
28. Nam EJ, Yoon H, Kim SW, et al: MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 14: 2690-2695, 2008.
29. Gonzales JC, Fink LM, Goodman OB Jr, Symanowski JT, Vogelzang NJ and Ward DC: Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer. Clin Genitourin Cancer 9: 39-45, 2011.
30. Yaman Agaoglu F, Kovancilar M, Dizdar Y, et al: Investigation of miR-21, miR-141, miR-221 in blood circulation of patients with prostate cancer. Tumour Biol 32: 583-588, 2011.
31. Cheng H, Zhang L, Cogdell DE, et al: Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PloS One 6: e17745, 2011.
32. Zaman MS, Shahryari V, Deng G, et al: Up-regulation of microRNA-21 correlates with lower kidney cancer survival. PLoS One 7: e31060, 2012.
33. Boquslawska J, Wojcicka A, Piekielko-Witkowska A, Master A and Nauman A: MiR-224 targets the 3'UTR of type 1 5'-iodothyronine deiodinase possibly contributing to tissue hypothyroidism in renal cancer. PLoS One 6: e24541, 2011.
34. Gibbons DL, Lin W, Creighton CJ, et al: Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev 23: 2140-2151, 2009.